Exelixis, Inc. (EXEL) - Financial and Strategic SWOT Analysis Review

Date: May 24, 2016
Pages: 65
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: EBC5B77E746EN
Leaflet:

Download PDF Leaflet

Exelixis, Inc. (EXEL) - Financial and Strategic SWOT Analysis Review
Exelixis, Inc. (EXEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Exelixis, Inc. (Exelixis) is a biopharmaceutical company. It focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company has two advanced product candidates: Cometriq (Cabozantinib), an inhibitor of multiple receptor tyrosine kinases; and Cobimetinib (GDC-0973/XL518), a potent, highly selective inhibitor of methyl ethyl ketone (MEK). The company's product pipeline includes GDC-0973 (XL518), a highly selective inhibitor of mitogen-activated protein kinase kinase(MEK); and XL888, a highly potent, orally bioavailable ATP-competitive inhibitor of heat shock protein 90 (HSP90). The company also enters into collaborative partnerships with pharmaceutical and biopharmaceutical companies to advance the development of potential therapies for cancer and other serious diseases. Exelixis is headquartered in South San Francisco, California, the US.

Exelixis, Inc. Key Recent Developments

May 04, 2016: Exelixis Announces First Quarter 2016 Financial Results and Provides Corporate Update
Feb 29, 2016: Exelixis Announces Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
Nov 10, 2015: Exelixis Announces Third Quarter 2015 Financial Results and Provides Corporate Update
Sep 24, 2015: Exelixis Announces Key Senior Leadership Hires in Medical Affairs, Sales, and Marketing to Support Commercialization of Cabozantinib and Cobimetinib
Aug 11, 2015: Exelixis Announces Second Quarter 2015 Financial Results and Provides Corporate Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Exelixis, Inc. - Key Facts
Exelixis, Inc. - Key Employees
Exelixis, Inc. - Key Employee Biographies
Exelixis, Inc. - Major Products and Services
Exelixis, Inc. - Pharmaceutical Pipeline Products Data
Exelixis, Inc., Pipeline Products by Therapy Area
Exelixis, Inc., Pipeline Products by Development Phase
Exelixis, Inc. - History
Exelixis, Inc. - Company Statement
Exelixis, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Exelixis, Inc. - Business Description
Exelixis, Inc. - Corporate Strategy
Exelixis, Inc. - SWOT Analysis
SWOT Analysis - Overview
Exelixis, Inc. - Strengths
Strength - Research and Development Activities
Strength - Business Performance: COMETRIQ
Strength - Strategic Collaborations
Exelixis, Inc. - Weaknesses
Weakness - Declining Operating Performance
Weakness - Discontinuation of Clinical Trials
Exelixis, Inc. - Opportunities
Opportunity - Regulatory Approvals and Pipeline Products
Opportunity - Strategic Partnerships
Opportunity - Market Potential: Oncology
Exelixis, Inc. - Threats
Threat - Stringent Government Regulations
Threat - Competitive Pressures
Threat - Reliance on Single Customer
Exelixis, Inc. - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Exelixis, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Exelixis, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Exelixis, Inc., Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 04, 2016: Exelixis Announces First Quarter 2016 Financial Results and Provides Corporate Update
Feb 29, 2016: Exelixis Announces Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
Nov 10, 2015: Exelixis Announces Third Quarter 2015 Financial Results and Provides Corporate Update
Sep 24, 2015: Exelixis Announces Key Senior Leadership Hires in Medical Affairs, Sales, and Marketing to Support Commercialization of Cabozantinib and Cobimetinib
Aug 11, 2015: Exelixis Announces Second Quarter 2015 Financial Results and Provides Corporate Update
Jul 15, 2015: Exelixis Appoints Chris Senner as Executive Vice President and Chief Financial Officer
Apr 30, 2015: Cabozantinib and Cobimetinib to Be Featured in Fourteen Presentations at 2015 ASCO Annual Meeting
Apr 30, 2015: Exelixis Announces First Quarter 2015 Financial Results and Provides Corporate Update
Feb 24, 2015: Exelixis Announces Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Exelixis, Inc., Key Facts
Exelixis, Inc., Key Employees
Exelixis, Inc., Key Employee Biographies
Exelixis, Inc., Major Products and Services
Exelixis, Inc., Number of Pipeline Products by Therapy Area
Exelixis, Inc., Number of Pipeline Products by Development Stage
Exelixis, Inc., Pipeline Products By Therapy Area and Development Phase
Exelixis, Inc., History
Exelixis, Inc., Subsidiaries
Exelixis, Inc., Key Competitors
Exelixis, Inc., Ratios based on current share price
Exelixis, Inc., Annual Ratios
Exelixis, Inc., Interim Ratios
Exelixis, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Exelixis, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Exelixis, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Exelixis, Inc., Pipeline Products by Therapy Area
Exelixis, Inc., Pipeline Products by Development Phase
Exelixis, Inc., Performance Chart (2011 - 2015)
Exelixis, Inc., Ratio Charts
Exelixis, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Exelixis, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016

COMPANIES MENTIONED

Ignyta, Inc.
Intercept Pharmaceuticals, Inc.
Array BioPharma Inc.
Genentech, Inc.
Astex Pharmaceuticals, Inc.
Senesco Technologies, Inc.
Skip to top


Ask Your Question

Exelixis, Inc. (EXEL) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: